The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.

Autor: Rodriguez-French A; Centro de Vacunas y Tratamiento de Enfermedades Febriles, Centro Especializado y Hospital Pediátrico San Fernando, La Sabana, Panama., Boghossian J, Gray GE, Nadler JP, Quinones AR, Sepulveda GE, Millard JM, Wannamaker PG

Publikováno v: Journal of acquired immune deficiency syndromes (1999) [J Acquir Immune Defic Syndr] 2004 Jan 01; Vol. 35 (1), pp. 22-32.